Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
101.21
+2.70 (+2.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Protagonist Receives $34 Million from Warrant Exercises
August 09, 2023
Via
ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
Via
ACCESSWIRE
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
↗
July 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Protagonist Therapeutics Reports Granting of Inducement Award
July 18, 2023
Via
ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
July 13, 2023
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.
Via
InvestorPlace
Expert Ratings for Protagonist Therapeutics
↗
July 06, 2023
Via
Benzinga
Where Protagonist Therapeutics Stands With Analysts
↗
June 12, 2023
Via
Benzinga
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
↗
June 09, 2023
Via
Talk Markets
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
June 01, 2023
Via
Investor Brand Network
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
↗
July 06, 2023
JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,
Via
Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
↗
July 06, 2023
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...
Via
Benzinga
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
↗
July 05, 2023
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 04, 2023
Via
Benzinga
Protagonist Therapeutics: Q1 Earnings Insights
↗
May 04, 2023
Via
Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
↗
April 27, 2023
Via
Benzinga
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
July 04, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
↗
July 03, 2023
Via
Benzinga
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
July 03, 2023
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.
Via
Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
↗
July 03, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...
Via
Benzinga
US Stocks Mixed; Dow Falls Over 50 Points
↗
July 03, 2023
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%...
Via
Benzinga
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
June 28, 2023
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.
Via
MarketBeat
Topics
Initial Public Offering
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
June 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 06, 2023
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 01, 2023
Via
ACCESSWIRE
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
↗
May 12, 2023
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of
Via
Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
↗
May 05, 2023
The company is targeting psoriasis with a first-ever mechanism that could rival leaders.
Via
Investor's Business Daily
Why Shares of Protagonist Therapeutics Rose This Week
↗
April 20, 2023
The company's lead pipeline candidate is making news.
Via
The Motley Fool
Why Protagonist Therapeutics Shares Are Nosediving
↗
April 05, 2023
Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
April 05, 2023
Via
Benzinga
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 04, 2023
Via
ACCESSWIRE
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
